2 weeks Ago By ABMN Staff
LPL Financial LLC reduced its stake in shares of Intellia Therapeutics, Inc. ( NASDAQ:NTLA – Free Report ) by 4.5% in the 4th quarter, HoldingsChannel.
com reports. The fund owned 54,041 shares of the company’s stock after selling 2,554 shares during the quarter. LPL Financial LLC’s holdings in Intellia Therapeutics were worth $630,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in NTLA. ARK Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 2.3% in the 4th quarter.
ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after purchasing an additional 280,946 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new position in Intellia Therapeutics in the fourth quarter valued at about $43,177,000.
Contrarius Group Holdings Ltd bought a new stake in Intellia Therapeutics during the fourth quarter worth about $11,798,000. American Century Companies Inc. increased its holdings in shares of Intellia Therapeutics by 3.
5% during the fourth quarter. American Century Companies Inc. now owns 453,821 shares of the company’s stock worth $5,292,000 after buying an additional 15,385 shares in the last quarter.
Finally, Raymond James Financial Inc. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $4,793,000. 88.
77% of the stock is owned by institutional investors. Analysts Set New Price Targets A number of equities research analysts recently commented on NTLA shares. Wells Fargo & Company decreased their price target on Intellia Therapeutics from $60.
00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Wolfe Research upgraded Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.
00 target price on the stock in a report on Monday. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $56.00 to $11.
00 in a research note on Monday, January 27th. HC Wainwright initiated coverage on shares of Intellia Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $30.
00 price target on the stock. Finally, Barclays decreased their price objective on shares of Intellia Therapeutics from $55.00 to $26.
00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.
com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $36.68. Intellia Therapeutics Stock Performance NTLA opened at $8.
11 on Thursday. The company has a fifty day moving average price of $8.78 and a two-hundred day moving average price of $11.
99. The firm has a market capitalization of $839.01 million, a PE ratio of -1.
49 and a beta of 2.23. Intellia Therapeutics, Inc.
has a 52 week low of $5.90 and a 52 week high of $28.18.
Intellia Therapeutics Company Profile ( Free Report ) Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. Recommended Stories Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. ( NASDAQ:NTLA – Free Report ). Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
